Lambert‐Niclot 2020.
Study characteristics | |||
Patient Sampling | Single‐group study to estimate sensitivity and specificity:
‐ samples submitted for RT‐PCR testing (n = 138) Recruitment: not stated Prospective or retrospective: unclear; testing conducted prospectively Number of samples (samples with confirmed SARS‐CoV‐2): 138 (94) |
||
Patient characteristics and setting | Setting: not stated Location: samples collected from virology laboratories of 3 university hospital groups from Assistance‐Publique‐Hôpitaux de Paris (APHP), (Saint‐Antoine‐Tenon‐Trousseau, Saint‐Louis‐Lariboisière and Kremlin Bicêtre‐Paul Brousse) Country: France Dates: 1‐15 April 2020 Symptoms and severity: not stated Demographics: not stated Exposure history: not stated |
||
Index tests | Test name: COVID‐19 Ag Respi‐Strip CORIS (no product code) Manufacturer: BioConcept, Gembloux, Belgium Antigen target: SARS‐CoV‐2 NP Antibody: monoclonal antibodies Test method: CGIA Samples used: NP swabs in VTM (collection process not described) Transport media: either of: COPAN UTM 3 mL, Virocult 1 mL, Eswab Amies 1 mL, 4MRT 3 mL, 0.9% NaCl buffer and cobas ROCHE Sample storage: no cooling or freezing step used Test operator: not stated; presume laboratory staff Definition of test positivity: not stated; as per manufacturer Blinding reported: not stated Timing of samples: not stated; presume on presentation |
||
Target condition and reference standard(s) | Reference standard: RT‐PCR (different kits used including RealStar Altona®, Anatolia®, cobas 6800 Roche®, Allplex™ 2019‐nCoV Assay Seegene®) Definition of non‐COVID cases: single negative PCR Genetic target(s): E gene Samples used: NP swabs (same as for index) Timing of reference standard: within a few hours after collection; time post onset of symptoms not reported Blinded to index test: unclear Incorporated index test: no |
||
Flow and timing | Time interval between index and reference tests: same sample, both tests conducted within a few hours All participants received same reference standard: yes (different kits) Missing data: none reported Uninterpretable results: 4 samples collected in cobas VTM gave invalid results and all samples in cobas medium were excluded Indeterminate results (index test): control lines reported as "barely visible" for 9 positive and 8 negative tests Indeterminate results (reference standard): none reported Unit of analysis: not reported, but samples tested on day of collection so considered to be 1 per participant |
||
Comparative | |||
Notes | Funding: no funding sources reported Publication status: accepted manuscript Source: Journal of Clinical Microbioloby Author COI: no conflict of interest statement reported |
||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Unclear | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | Unclear | ||
Did the study avoid inappropriate inclusions? | Unclear | ||
Could the selection of patients have introduced bias? | Unclear risk | ||
Are there concerns that the included patients and setting do not match the review question? | Unclear | ||
DOMAIN 2: Index Test (Antigen tests) | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Unclear | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Could the conduct or interpretation of the index test have introduced bias? | Unclear risk | ||
Are there concerns that the index test, its conduct, or interpretation differ from the review question? | Unclear | ||
DOMAIN 2: Index Test (Rapid molecular tests) | |||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | No | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Unclear | ||
Reference standard does not incorporate result of index test? | Yes | ||
Could the reference standard, its conduct, or its interpretation have introduced bias? | High risk | ||
Are there concerns that the target condition as defined by the reference standard does not match the question? | High | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all patients receive the same reference standard? | Yes | ||
Were all patients included in the analysis? | No | ||
Did all participants receive a reference standard? | Yes | ||
Were results presented per patient? | Yes | ||
Could the patient flow have introduced bias? | High risk |